Our results further suggest that esophageal carcinoma, like melanoma, could exploit the PD1 pathway to promote cancer progression both by dampening tumor-specific immunity via engagement of TIL-expressed PD1 and by triggering tumor cell-intrinsic growth signals via engagement of cancer cell-expressed PD1. This evidence concerns the gene PDCD1 and neoplasm.